Reuters logo
BRIEF-Novartis Says Premenopausal Women Taking Kisqali Benefited For Longer Time Until Health-Related QOL Deterioration
December 6, 2017 / 7:27 PM / in 7 days

BRIEF-Novartis Says Premenopausal Women Taking Kisqali Benefited For Longer Time Until Health-Related QOL Deterioration

Dec 6 (Reuters) - Novartis Ag:

* NOVARTIS KISQALI IS FIRST AND ONLY CDK4/6 INHIBITOR TO SHOW SUPERIOR MEDIAN PFS COMPARED TO ORAL ENDOCRINE THERAPY AS FIRST-LINE TREATMENT IN A PROSPECTIVE, RANDOMIZED PHASE III TRIAL DEDICATED TO PREMENOPAUSAL WOMEN WITH HR+/HER2- ADVANCED BREAST CANCER

* NOVARTIS - PREMENOPAUSAL WOMEN TAKING KISQALI BENEFITED FOR LONGER TIME UNTIL HEALTH-RELATED QOL DETERIORATION VERSUS THOSE TAKING ENDOCRINE THERAPY ALONE

* NOVARTIS - WOMEN TAKING KISQALI ALSO HAD A “CLINICALLY MEANINGFUL” IMPROVEMENT IN PAIN SYMPTOMS AS EARLY AS EIGHT WEEKS

* NOVARTIS - NO NEW SAFETY SIGNALS WERE OBSERVED IN MONALEESA-7 TRIAL

* NOVARTIS AG - COMBINATION TREATMENT WITH KISQALI WAS WELL TOLERATED WITH A DISCONTINUATION RATE DUE TO ADVERSE EVENTS OF 3.6% Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below